Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sideris

Showing results (1171-1180 of 1,209) with videos related to

Pageof 121
Sort By:
Non-Coding RNA|April 27, 2023
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-12Patrick K T Shiu, Mirolyuba Ilieva, Anja Holm, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Non-Coding RNA|November 24, 2025
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-14El Cheima Mhamedi, Florent Hubé, Suresh K Alahari, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Peroxisome proliferator-activated receptor gamma ( <i>PPARG</i> )-mediated myocardial salvage in acute myocardial infarction managed with left ventricular unloading and coronary reperfusionJoseph R Visker, Eleni Tseliou, Christos P Kyriakopoulos, et al.
Resuscitation|July 5, 2022
Lack of early etiologic investigations in young sudden cardiac deathArdalan Sharifzadehgan, Bamba Gaye, Wulfran Bougouin, et al.
Journal of Medicinal Chemistry|October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case StudyRobert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2022
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenaseBinQing Wei, Kirk Robarge, Sharada S Labadie, et al.
JAMA Cardiology|January 31, 2024
Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF ScoreIosif Taleb, Christos P Kyriakopoulos, Robyn Fong, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Pageof 121

Showing results (1171-1180 of 1,209) with videos related to

Sort By:
Pageof 121
Non-Coding RNA|April 27, 2023
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-12Patrick K T Shiu, Mirolyuba Ilieva, Anja Holm, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Non-Coding RNA|November 24, 2025
The <i>Non-Coding RNA</i> Journal Club: Highlights on Recent Papers-14El Cheima Mhamedi, Florent Hubé, Suresh K Alahari, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Peroxisome proliferator-activated receptor gamma ( <i>PPARG</i> )-mediated myocardial salvage in acute myocardial infarction managed with left ventricular unloading and coronary reperfusionJoseph R Visker, Eleni Tseliou, Christos P Kyriakopoulos, et al.
Resuscitation|July 5, 2022
Lack of early etiologic investigations in young sudden cardiac deathArdalan Sharifzadehgan, Bamba Gaye, Wulfran Bougouin, et al.
Journal of Medicinal Chemistry|October 13, 2015
Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case StudyRobert Heald, Krista K Bowman, Marian C Bryan, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2022
Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenaseBinQing Wei, Kirk Robarge, Sharada S Labadie, et al.
JAMA Cardiology|January 31, 2024
Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF ScoreIosif Taleb, Christos P Kyriakopoulos, Robyn Fong, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Pageof 121